HomeCompareFSRPF vs JNJ

FSRPF vs JNJ: Dividend Comparison 2026

FSRPF yields 4.48% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FSRPF wins by $14.5K in total portfolio value
10 years
FSRPF
FSRPF
● Live price
4.48%
Share price
$0.79
Annual div
$0.04
5Y div CAGR
19.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.7K
Annual income
$5,289.22
Full FSRPF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — FSRPF vs JNJ

📍 FSRPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFSRPFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FSRPF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FSRPF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FSRPF
Annual income on $10K today (after 15% tax)
$380.66/yr
After 10yr DRIP, annual income (after tax)
$4,495.84/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, FSRPF beats the other by $509.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FSRPF + JNJ for your $10,000?

FSRPF: 50%JNJ: 50%
100% JNJ50/50100% FSRPF
Portfolio after 10yr
$37.5K
Annual income
$4,989.31/yr
Blended yield
13.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FSRPF
No analyst data
Altman Z
0.6
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FSRPF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFSRPFJNJ
Forward yield4.48%2.13%
Annual dividend / share$0.04$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR19.4%28%
Portfolio after 10y$44.7K$30.3K
Annual income after 10y$5,289.22$4,689.40
Total dividends collected$20.8K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FSRPF vs JNJ ($10,000, DRIP)

YearFSRPF PortfolioFSRPF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,235$534.71$10,592$272.30+$643.00FSRPF
2$12,691$670.35$11,289$357.73+$1.4KFSRPF
3$14,425$845.04$12,123$472.89+$2.3KFSRPF
4$16,506$1,071.76$13,141$629.86+$3.4KFSRPF
5$19,030$1,368.54$14,408$846.81+$4.6KFSRPF
6$22,123$1,760.65$16,021$1,151.60+$6.1KFSRPF
7$25,956$2,283.98$18,122$1,588.22+$7.8KFSRPF
8$30,763$2,990.20$20,930$2,228.20+$9.8KFSRPF
9$36,871$3,954.70$24,792$3,191.91+$12.1KFSRPF
10$44,741$5,289.22$30,274$4,689.40+$14.5KFSRPF

FSRPF vs JNJ: Complete Analysis 2026

FSRPFStock

Frasers Property Limited, an investment holding company, develops, invests in, and manages a portfolio of real estate properties. The company's asset portfolio includes integrated, residential, hospitality, commercial and business parks, retail, and logistics and industrial properties in Singapore, Australia, Europe, China, Thailand, Southeast Asia, and internationally. It owns and/or operates serviced apartments and hotels in approximately 70 cities across Asia, Australia, Europe, the Middle East, and Africa. The company also acts as a sponsor of two real estate investment trusts (REITs) listed on the SGX-ST that comprises Frasers Centrepoint Trust, and Frasers Logistics & Commercial Trust focused on retail, commercial, and industrial properties; and one stapled trust listed on the SGX-ST that include Frasers Hospitality Trust focused on hospitality properties; and two REITs listed on the Stock Exchange of Thailand, which include Frasers Property (Thailand) Public Company Limited, a sponsor of Frasers Property Thailand Industrial Freehold & Leasehold REIT that focuses on industrial and logistics properties in Thailand, as well as Golden Ventures Leasehold Real Estate Investment Trust, which focuses on commercial properties. The company was formerly known as Frasers Centrepoint Limited and changed its name to Frasers Property Limited in February 2018. The company was incorporated in 1963 and is headquartered in Singapore.

Full FSRPF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this FSRPF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FSRPF vs SCHDFSRPF vs JEPIFSRPF vs OFSRPF vs KOFSRPF vs MAINFSRPF vs ABBVFSRPF vs MRKFSRPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.